Cargando…
PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives
Overexpression of urokinase-type plasminogen activator receptors (uPAR) represents an important biomarker for aggressiveness in most common malignant diseases, including prostate cancer (PC). Accordingly, uPAR expression either assessed directly in malignant PC tissue or assessed directly in plasma...
Autores principales: | Skovgaard, Dorthe, Persson, Morten, Kjaer, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118403/ https://www.ncbi.nlm.nih.gov/pubmed/27933281 http://dx.doi.org/10.1007/s40336-016-0197-4 |
Ejemplares similares
-
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications
por: Persson, Morten, et al.
Publicado: (2013) -
First-in-human uPAR PET: Imaging of Cancer Aggressiveness
por: Persson, Morten, et al.
Publicado: (2015) -
Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013) -
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
por: Zhai, Bing-Tao, et al.
Publicado: (2022) -
Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients
por: Risør, Louise Madeleine, et al.
Publicado: (2022)